This study looks at how a drug called TAR-200 works with another drug called cetrelimab and cetrelimab by itself in treating bladder cancer that has spread into the muscles. Bladder cancer is a common type of cancer, and some people have a type called muscle-invasive bladder cancer (MIBC). TAR-200 is a special system that delivers medicine directly into the bladder. Cetrelimab is a type of antibody that helps the body’s immune system fight cancer.

The study has three parts: Screening, Treatment, and Follow-up, and it will take about 2 years and 6 months to complete. Researchers will check how well the treatment works, its safety, and how the body processes the drugs. People can join the study if they have specific types of bladder cancer and meet certain health criteria. However, they cannot join if they had certain past treatments or health conditions.

• The study lasts up to 2 years and 6 months.
• Participants undergo Screening, Treatment, and Follow-up phases.
• Eligibility depends on specific health criteria and past treatments.